{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:16:35Z","timestamp":1792638995718,"version":"4.5.0"},"reference-count":202,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The standard therapies in lymphoma have predominantly focused on targeting tumor cells with less of a focus on the tumor microenvironment (TME), which plays a critical role in favoring tumor growth and survival. Such an approach may result in increasingly refractory disease with progressively reduced responses to subsequent treatments. To overcome this hurdle, targeting the TME has emerged as a new therapeutic strategy. The TME consists of T and B lymphocytes, tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), cancer-associated fibroblasts (CAFs), and other components. Understanding the TME can lead to a comprehensive approach to managing lymphoma, resulting in therapeutic strategies that target not only cancer cells, but also the supportive environment and thereby ultimately improve survival of lymphoma patients. Here, we review the normal function of different components of the TME, the impact of their aberrant behavior in B cell lymphoma and the current TME-direct therapeutic avenues.<\/jats:p>","DOI":"10.1186\/s13046-022-02579-9","type":"journal-article","created":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T21:02:26Z","timestamp":1672261346000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Insights into the tumor microenvironment of B cell lymphoma"],"prefix":"10.1186","volume":"41","author":[{"given":"Wern Lynn","family":"Ng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-3757","authenticated-orcid":false,"given":"Patrizia","family":"Mondello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"2579_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.immuni.2016.09.001","volume":"45","author":"L Mesin","year":"2016","unstructured":"Mesin L, Ersching J, Victora GD. Germinal center B cell dynamics. Immunity. 2016;45:471\u201382 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27653600.","journal-title":"Immunity."},{"key":"2579_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nri3814","volume":"15","author":"K Basso","year":"2015","unstructured":"Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015;15:172\u201384 https:\/\/pubmed.ncbi.nlm.nih.gov\/25712152\/.","journal-title":"Nat Rev Immunol"},{"key":"2579_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10676951.","journal-title":"Nature."},{"key":"2579_CR4","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29713087.","journal-title":"Nat Med"},{"key":"2579_CR5","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29641966.","journal-title":"N Engl J Med"},{"key":"2579_CR6","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","volume":"351","author":"SS Dave","year":"2004","unstructured":"Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159\u201369 http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMoa041869.","journal-title":"N Engl J Med"},{"key":"2579_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41408-021-00521-4","volume":"11","author":"P Mondello","year":"2021","unstructured":"Mondello P, Fama A, Larson MC, Feldman AL, Villasboas JC, Yang ZZ, et al. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer J. 2021;11:130 https:\/\/pubmed.ncbi.nlm.nih.gov\/34267181\/.","journal-title":"Blood Cancer J"},{"key":"2579_CR8","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov N, Bagaev A, Revuelta MV, Phillip JM, Cacciapuoti MT, Antysheva Z, et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 2021;11:1468\u201389 https:\/\/pubmed.ncbi.nlm.nih.gov\/33541860\/.","journal-title":"Cancer Discov"},{"issue":"10","key":"2579_CR9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","volume":"39","author":"CB Steen","year":"2021","unstructured":"Steen CB, Luca BA, Esfahani MS, Azizi A, Sworder BJ, Nabet BY, et al. The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma. Cancer Cell. 2021;39(10):1422\u201337 http:\/\/www.cell.com\/article\/S1535610821004517\/fulltext Elsevier.","journal-title":"Cancer Cell"},{"key":"2579_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2159-8290.CD-19-0116","volume":"10","author":"P Mondello","year":"2020","unstructured":"Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discov. 2020;10:440\u201359 http:\/\/cancerdiscovery.aacrjournals.org\/lookup\/doi\/10.1158\/2159-8290.CD-19-0116.","journal-title":"Cancer Discov"},{"key":"2579_CR11","first-page":"535","volume":"51","author":"SN Meyer","year":"2019","unstructured":"Meyer SN, Scuoppo C, Vlasevska S, Bal E, Holmes AB, Holloman M, et al. Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma. Immunity Cell Press. 2019;51:535\u2013547.e9.","journal-title":"Immunity Cell Press"},{"key":"2579_CR12","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","volume":"9","author":"D Ennishi","year":"2019","unstructured":"Ennishi D, Takata K, B\u00e9guelin W, Duns G, Mottok A, Farinha P, et al. Molecular and genetic characterization of MHC deficiency identifies ezh2 as therapeutic target for enhancing immune recognition. Cancer Discov. 2019;9:546\u201363 https:\/\/pubmed.ncbi.nlm.nih.gov\/30705065\/.","journal-title":"Cancer Discov"},{"key":"2579_CR13","doi-asserted-by":"publisher","first-page":"826594","DOI":"10.3389\/fgene.2022.826594","volume":"13","author":"P Mondello","year":"2022","unstructured":"Mondello P, Ansell SM, Nowakowski GS. Immune epigenetic crosstalk between malignant B cells and the tumor microenvironment in B cell lymphoma. Front Genet. 2022;13:826594 https:\/\/pubmed.ncbi.nlm.nih.gov\/35237302\/.","journal-title":"Front Genet"},{"key":"2579_CR14","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ccell.2021.10.007","volume":"39","author":"P Mondello","year":"2021","unstructured":"Mondello P, Ansell SM. PHOENIX rises: genomic-based therapies for diffuse large B cell lymphoma. Cancer Cell. 2021;39:1570\u20132 https:\/\/pubmed.ncbi.nlm.nih.gov\/34739842\/.","journal-title":"Cancer Cell"},{"key":"2579_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41:529\u201342 https:\/\/pubmed.ncbi.nlm.nih.gov\/25367570\/.","journal-title":"Immunity."},{"key":"2579_CR16","doi-asserted-by":"publisher","first-page":"eabe5146","DOI":"10.1126\/science.abe5146","volume":"373","author":"JT Jacobsen","year":"2021","unstructured":"Jacobsen JT, Hu W, Castro TBR, Solem S, Galante A, Lin Z, et al. Expression of Foxp3 by T follicular helper cells in end-stage germinal centers. Science. 2021;373:eabe5146 https:\/\/pubmed.ncbi.nlm.nih.gov\/34437125\/.","journal-title":"Science"},{"key":"2579_CR17","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/10245332.2017.1300623","volume":"22","author":"DM Zhou","year":"2017","unstructured":"Zhou DM, Xu YX, Zhang LY, Sun Y, Wang ZY, Yuan YQ, et al. The role of follicular T helper cells in patients with malignant lymphoid disease. Hematology. 2017;22:412\u20138 https:\/\/pubmed.ncbi.nlm.nih.gov\/28281408\/.","journal-title":"Hematology"},{"key":"2579_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.intimp.2018.05.025","volume":"61","author":"Z Cha","year":"2018","unstructured":"Cha Z, Gu H, Zang Y, Wang Z, Li J, Huang W, et al. The prevalence and function of CD4+CXCR5+Foxp3+ follicular regulatory T cells in diffuse large B cell lymphoma. Int Immunopharmacol. 2018;61:132\u20139 https:\/\/pubmed.ncbi.nlm.nih.gov\/29870918\/.","journal-title":"Int Immunopharmacol"},{"key":"2579_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/imr.12860","volume":"296","author":"MA Mintz","year":"2020","unstructured":"Mintz MA, Cyster JG. T follicular helper cells in germinal center B cell selection and lymphomagenesis. Immunol Rev. 2020;296:48\u201361 https:\/\/pubmed.ncbi.nlm.nih.gov\/32412663.","journal-title":"Immunol Rev"},{"key":"2579_CR20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.4049\/jimmunol.181.2.1001","volume":"181","author":"M Travert","year":"2008","unstructured":"Travert M, Ame-Thomas P, Pangault C, Morizot A, Micheau O, Semana G, et al. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-\u03baB activation and up-regulation of c-FLIP and Bcl-xL. J Immunol. 2008;181:1001\u201311 https:\/\/www.jimmunol.org\/content\/181\/2\/1001.","journal-title":"J Immunol"},{"key":"2579_CR21","doi-asserted-by":"publisher","first-page":"e97597","DOI":"10.1371\/journal.pone.0097597","volume":"9","author":"MT Brady","year":"2014","unstructured":"Brady MT, Hilchey SP, Hyrien O, Spence SA, Bernstein SH. Mesenchymal stromal cells support the viability and differentiation of follicular lymphoma-infiltrating follicular helper T-cells. PLoS One. 2014;9:e97597 https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0097597.","journal-title":"PLoS One"},{"key":"2579_CR22","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2008-02-138933","volume":"112","author":"KR Calvo","year":"2008","unstructured":"Calvo KR, Dabir B, Kovach A, Devor C, Bandle R, Bond A, et al. IL-4 protein expression and basal activation of Erk in vivo in follicular lymphoma. Blood. 2008;112:3818\u201326 https:\/\/pubmed.ncbi.nlm.nih.gov\/18682601\/.","journal-title":"Blood."},{"key":"2579_CR23","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.4049\/jimmunol.1201363","volume":"190","author":"S Rawal","year":"2013","unstructured":"Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, et al. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol. 2013;190:6681\u201393 http:\/\/www.jimmunol.org\/cgi\/doi\/10.4049\/jimmunol.1201363.","journal-title":"J Immunol"},{"key":"2579_CR24","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1038\/leu.2010.223","volume":"24","author":"C Pangault","year":"2010","unstructured":"Pangault C, Am\u00e9-Thomas P, Ruminy P, Rossille D, Caron G, Baia M, et al. Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent T(FH)-B cell axis. Leukemia. 2010;24:2080\u20139 http:\/\/www.nature.com\/articles\/leu2010223.","journal-title":"Leukemia."},{"key":"2579_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.humimm.2020.05.008","volume":"81","author":"X Ma","year":"2020","unstructured":"Ma X, Zha J, He J, Chen L, Huang J, Wu W, et al. T follicular helper cell-mediated IL-21 production suppresses FOXP3 expression of T follicular regulatory-like cells in diffuse large B cell lymphoma patients. Hum Immunol. 2020;81:452\u20139 https:\/\/pubmed.ncbi.nlm.nih.gov\/32534760\/.","journal-title":"Hum Immunol"},{"key":"2579_CR26","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2643-3230.BCD-21-0075","volume":"3","author":"G Han","year":"2022","unstructured":"Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, et al. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov. 2022;3:428\u201343 https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/3\/5\/428\/708353\/Follicular-Lymphoma-Microenvironment.","journal-title":"Blood Cancer Discov"},{"key":"2579_CR27","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1172\/JCI57175","volume":"123","author":"A Chaudhry","year":"2013","unstructured":"Chaudhry A, Rudensky AY. Control of inflammation by integration of environmental cues by regulatory T cells. J Clin Invest. 2013;123:939\u201344 https:\/\/pubmed.ncbi.nlm.nih.gov\/23454755\/.","journal-title":"J Clin Invest"},{"key":"2579_CR28","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:986\u201392 https:\/\/pubmed.ncbi.nlm.nih.gov\/12612578\/.","journal-title":"Nat Immunol"},{"key":"2579_CR29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","volume":"30","author":"SZ Josefowicz","year":"2012","unstructured":"Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531\u201364.","journal-title":"Annu Rev Immunol"},{"key":"2579_CR30","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-11-3687","volume":"72","author":"A Facciabene","year":"2012","unstructured":"Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72:2162\u201371 https:\/\/aacrjournals.org\/cancerres\/article\/72\/9\/2162\/584187\/T-Regulatory-Cells-Key-Players-in-Tumor-Immune.","journal-title":"Cancer Res"},{"key":"2579_CR31","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","volume":"107","author":"ZZ Yang","year":"2006","unstructured":"Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107:3639\u201346 https:\/\/pubmed.ncbi.nlm.nih.gov\/16403912\/.","journal-title":"Blood."},{"key":"2579_CR32","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","volume":"108","author":"J Carreras","year":"2006","unstructured":"Carreras J, Lopez-Guillermo A, Fox BC, Colomo L, Martinez A, Roncador G, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957\u201364 http:\/\/www.bloodjournal.org\/cgi\/doi\/10.1182\/blood-2006-04-018218.","journal-title":"Blood."},{"key":"2579_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1158\/1078-0432.CCR-09-2487","volume":"16","author":"BE Wahlin","year":"2010","unstructured":"Wahlin BE, Aggarwal M, Montes-Moreno S, Gonzalez LF, Roncador G, Sanchez-Verde L, et al. A unifying microenvironment model in follicular lymphoma: outcome is predicted by programmed death-1-positive, regulatory, cytotoxic, and helper T cells and macrophages. Clin Cancer Res. 2010;16:637\u201350 https:\/\/aacrjournals.org\/clincancerres\/article\/16\/2\/637\/75610\/A-Unifying-Microenvironment-Model-in-Follicular.","journal-title":"Clin Cancer Res"},{"key":"2579_CR34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3324\/haematol.11702","volume":"93","author":"A Tzankov","year":"2008","unstructured":"Tzankov A, Meier C, Hirschmann P, Went P, Pileri SA, Dirnhofer S. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin\u2019s lymphoma. Haematologica. 2008;93:193\u2013200 https:\/\/pubmed.ncbi.nlm.nih.gov\/18223287\/.","journal-title":"Haematologica."},{"key":"2579_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/10428190701824536","volume":"49","author":"NR Lee","year":"2008","unstructured":"Lee NR, Song EK, Jang KY, Choi HN, Moon WS, Kwon K, et al. Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma. 2008;49:247\u201356 https:\/\/pubmed.ncbi.nlm.nih.gov\/18231910\/.","journal-title":"Leuk Lymphoma"},{"key":"2579_CR36","doi-asserted-by":"publisher","first-page":"10145","DOI":"10.1158\/0008-5472.CAN-06-1822","volume":"66","author":"ZZ Yang","year":"2006","unstructured":"Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8+ T-cell function by CD4+CD25 + regulatory T cells in B-cell non-Hodgkin\u2019s lymphoma. Cancer Res. 2006;66:10145\u201352 https:\/\/pubmed.ncbi.nlm.nih.gov\/17047079\/.","journal-title":"Cancer Res"},{"key":"2579_CR37","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/bloodadvances.2016000885","volume":"1","author":"S Nakayama","year":"2017","unstructured":"Nakayama S, Yokote T, Akioka T, Hiraoka N, Nishiwaki U, Miyoshi T, et al. Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified. Blood Adv. 2017;1:486\u201393 https:\/\/ashpublications.org\/bloodadvances\/article\/1\/8\/486\/15602\/Infiltration-of-effector-regulatory-T-cells.","journal-title":"Blood Adv"},{"key":"2579_CR38","doi-asserted-by":"publisher","first-page":"5217","DOI":"10.1158\/1078-0432.CCR-20-0558","volume":"26","author":"ZZ Yang","year":"2020","unstructured":"Yang ZZ, Kim HJ, Wu H, Jalali S, Tang X, Krull JE, et al. TIGIT expression is associated with T-cell suppression and exhaustion and predicts clinical outcome and anti-PD-1 response in follicular lymphoma. Clin Cancer Res. 2020;26:5217\u201331 https:\/\/pubmed.ncbi.nlm.nih.gov\/32631956\/.","journal-title":"Clin Cancer Res"},{"key":"2579_CR39","doi-asserted-by":"publisher","first-page":"4322","DOI":"10.1158\/1078-0432.CCR-22-0977","volume":"28","author":"X Tang","year":"2022","unstructured":"Tang X, Yang Z-Z, Kim HJ, Anagnostou T, Yu Y, Wu X, et al. Phenotype, function, and clinical significance of CD26+ and CD161+Tregs in splenic marginal zone lymphoma. Clin Cancer Res. 2022;28:4322\u201335 https:\/\/pubmed.ncbi.nlm.nih.gov\/35686915\/.","journal-title":"Clin Cancer Res"},{"key":"2579_CR40","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/cancers14040860","volume":"14","author":"N Profit\u00f3s-Pelej\u00e0","year":"2022","unstructured":"Profit\u00f3s-Pelej\u00e0 N, Santos JC, Mar\u00edn-Niebla A, Rou\u00e9 G, Ribeiro ML. Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas. Cancers (Basel). 2022;14:860 https:\/\/pubmed.ncbi.nlm.nih.gov\/35205606\/.","journal-title":"Cancers (Basel)"},{"key":"2579_CR41","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","volume":"114","author":"AG Ramsay","year":"2009","unstructured":"Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, MacDougall F, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114:4713\u201320 https:\/\/pubmed.ncbi.nlm.nih.gov\/19786615\/.","journal-title":"Blood."},{"key":"2579_CR42","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3389\/fimmu.2016.00228","volume":"7","author":"P Pandiyan","year":"2016","unstructured":"Pandiyan P, Younes SA, Ribeiro SP, Talla A, McDonald D, Bhaskaran N, et al. Mucosal regulatory T cells and T helper 17 cells in HIV-associated immune activation. Front Immunol. 2016;7:228 https:\/\/pubmed.ncbi.nlm.nih.gov\/27379092\/.","journal-title":"Front Immunol"},{"key":"2579_CR43","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10238-016-0411-8","volume":"17","author":"MA Grygorowicz","year":"2017","unstructured":"Grygorowicz MA, Borycka IS, Nowak E, Paszkiewicz-Kozik E, Rymkiewicz G, B\u0142achnio K, et al. Lenalidomide potentiates CD4+CD25+Treg-related suppression of lymphoma B-cell proliferation. Clin Exp Med. 2017;17:193\u2013207 https:\/\/pubmed.ncbi.nlm.nih.gov\/26961690\/.","journal-title":"Clin Exp Med"},{"key":"2579_CR44","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.3390\/cancers13215535","volume":"13","author":"C Tarantelli","year":"2021","unstructured":"Tarantelli C, Argnani L, Zinzani PL, Bertoni F. PI3K\u03b4 Inhibitors as Immunomodulatory Agents for the Treatment of Lymphoma Patients. Cancers (Basel). 2021;13:5535 \/pmc\/articles\/PMC8582887.","journal-title":"Cancers (Basel)"},{"key":"2579_CR45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-018-0457-0","volume":"6","author":"LS Carnevalli","year":"2018","unstructured":"Carnevalli LS, Sinclair C, Taylor MA, Gutierrez PM, Langdon S, Coenen-Stass AML, et al. PI3K\u03b1\/\u03b4 inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity 11 medical and health sciences 1107 immunology. J Immunother Cancer. 2018;6:1\u201314 https:\/\/jitc.biomedcentral.com\/articles\/10.1186\/s40425-018-0457-0.","journal-title":"J Immunother Cancer"},{"key":"2579_CR46","first-page":"621","volume":"50","author":"H Jin","year":"2021","unstructured":"Jin H, Zhou Y, Wang L. The mechanism of rapamycin in promoting asthmatic regulatory T cell differentiation and function. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2021;50:621\u20136 https:\/\/pubmed.ncbi.nlm.nih.gov\/34986526\/.","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"2579_CR47","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","volume":"224","author":"BT Fife","year":"2008","unstructured":"Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166\u201382 https:\/\/pubmed.ncbi.nlm.nih.gov\/18759926\/.","journal-title":"Immunol Rev"},{"key":"2579_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson RC, Maus M, v. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361 https:\/\/pubmed.ncbi.nlm.nih.gov\/18759926.","journal-title":"Nat Rev Cancer"},{"key":"2579_CR49","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933\u201359 https:\/\/pubmed.ncbi.nlm.nih.gov\/33811125\/.","journal-title":"Cancer Discov"},{"key":"2579_CR50","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/cancers13061440","volume":"13","author":"N Sobhani","year":"2021","unstructured":"Sobhani N, Tardiel-Cyril DR, Davtyan A, Generali D, Roudi R, Li Y. CTLA-4 in regulatory T cells for cancer immunotherapy. Cancers (Basel). 2021;13:1440 https:\/\/pubmed.ncbi.nlm.nih.gov\/33809974\/.","journal-title":"Cancers (Basel)"},{"key":"2579_CR51","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1158\/1078-0432.CCR-19-0438","volume":"25","author":"JM Tuscano","year":"2019","unstructured":"Tuscano JM, Maverakis E, Groshen S, Tsao-Wei D, Luxardi G, Merleev AA, et al. A phase I study of the combination of rituximab and ipilimumab in patients with relapsed\/ refractory B-cell lymphoma. Clin Cancer Res. 2019;25:7004\u201313 https:\/\/pubmed.ncbi.nlm.nih.gov\/31481504\/.","journal-title":"Clin Cancer Res"},{"key":"2579_CR52","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei SC, Levine JH, Cogdill AP, Zhao Y, Anang NAAS, Andrews MC, et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell. 2017;170:1120\u201333 https:\/\/pubmed.ncbi.nlm.nih.gov\/28803728\/.","journal-title":"Cell."},{"key":"2579_CR53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8 https:\/\/pubmed.ncbi.nlm.nih.gov\/28803728\/.","journal-title":"J Immunother Cancer"},{"key":"2579_CR54","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","volume":"6","author":"RY Huang","year":"2017","unstructured":"Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561 https:\/\/pubmed.ncbi.nlm.nih.gov\/28197366\/.","journal-title":"Oncoimmunology."},{"key":"2579_CR55","doi-asserted-by":"publisher","first-page":"27359","DOI":"10.18632\/oncotarget.4751","volume":"6","author":"RY Huang","year":"2015","unstructured":"Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6:27359\u201377 https:\/\/pubmed.ncbi.nlm.nih.gov\/26318293\/.","journal-title":"Oncotarget."},{"key":"2579_CR56","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","volume":"15","author":"SM Ansell","year":"2009","unstructured":"Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15:6446\u201353 https:\/\/pubmed.ncbi.nlm.nih.gov\/19808874\/.","journal-title":"Clin Cancer Res"},{"key":"2579_CR57","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1038\/ni1271","volume":"6","author":"C Zhu","year":"2005","unstructured":"Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245\u201353 https:\/\/pubmed.ncbi.nlm.nih.gov\/16286920\/.","journal-title":"Nat Immunol"},{"key":"2579_CR58","doi-asserted-by":"publisher","first-page":"15659","DOI":"10.1038\/srep15659","volume":"5","author":"CW Kang","year":"2015","unstructured":"Kang CW, Dutta A, Chang LY, Mahalingam J, Lin YC, Chiang JM, et al. Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer. Sci Rep. 2015;5:15659 https:\/\/pubmed.ncbi.nlm.nih.gov\/26493689\/.","journal-title":"Sci Rep"},{"key":"2579_CR59","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2217\/imt-2017-0024","volume":"9","author":"AW Hahn","year":"2017","unstructured":"Hahn AW, Gill DM, Pal SK, Agarwal N. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. Immunotherapy. 2017;9:681\u201392 https:\/\/pubmed.ncbi.nlm.nih.gov\/28653573\/.","journal-title":"Immunotherapy."},{"key":"2579_CR60","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/ni.1674","volume":"10","author":"X Yu","year":"2009","unstructured":"Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009;10:48\u201357 https:\/\/pubmed.ncbi.nlm.nih.gov\/19011627.","journal-title":"Nat Immunol"},{"key":"2579_CR61","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The Immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell. 2014;26:923\u201337 https:\/\/pubmed.ncbi.nlm.nih.gov\/25465800\/.","journal-title":"Cancer Cell"},{"key":"2579_CR62","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunp\u00e4\u00e4","year":"2020","unstructured":"Harjunp\u00e4\u00e4 H, Guillerey C. TIGIT as an emerging immune checkpoint. Clin Exp Immunol. 2020;200:108\u201319 https:\/\/pubmed.ncbi.nlm.nih.gov\/31828774\/.","journal-title":"Clin Exp Immunol"},{"key":"2579_CR63","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/87720","volume":"2","author":"SM Kaech","year":"2001","unstructured":"Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in na\u00efve cells. Nat Immunol. 2001;2:415\u201322 https:\/\/pubmed.ncbi.nlm.nih.gov\/11323695\/.","journal-title":"Nat Immunol"},{"key":"2579_CR64","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/nature25144","volume":"552","author":"B Youngblood","year":"2017","unstructured":"Youngblood B, Hale JS, Kissick HT, Ahn E, Xu X, Wieland A, et al. Effector CD8 T cells dedifferentiate into long-lived memory cells. Nature. 2017;552:404\u20139 https:\/\/pubmed.ncbi.nlm.nih.gov\/29236683\/.","journal-title":"Nature."},{"key":"2579_CR65","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41590-021-00949-7","volume":"22","author":"JL Collier","year":"2021","unstructured":"Collier JL, Weiss SA, Pauken KE, Sen DR, Sharpe AH. Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nat Immunol. 2021;22:809\u201319 https:\/\/pubmed.ncbi.nlm.nih.gov\/34140679\/.","journal-title":"Nat Immunol"},{"key":"2579_CR66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2567.2011.03470.x","volume":"134","author":"M Strioga","year":"2011","unstructured":"Strioga M, Pasukoniene V, Characiejus D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology. 2011;134:17\u201332 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21711350.","journal-title":"Immunology"},{"key":"2579_CR67","doi-asserted-by":"publisher","first-page":"584937","DOI":"10.3389\/fimmu.2020.584937","volume":"11","author":"F Alotaibi","year":"2021","unstructured":"Alotaibi F, Vincent M, Min WP, Koropatnick J. Reduced CD5 on CD8+ T cells in tumors but not lymphoid organs is associated with increased activation and effector function. Front Immunol. 2021;11:584937 https:\/\/pubmed.ncbi.nlm.nih.gov\/33584650\/.","journal-title":"Front Immunol"},{"key":"2579_CR68","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining \u2018T cell exhaustion\u2019. Nat Rev Immunol. 2019;19:665\u201374 https:\/\/pubmed.ncbi.nlm.nih.gov\/31570879\/.","journal-title":"Nat Rev Immunol"},{"key":"2579_CR69","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-06-1734","volume":"13","author":"BE Wahlin","year":"2007","unstructured":"Wahlin BE, Sander B, Christensson B, Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res. 2007;13:338\u201397 https:\/\/pubmed.ncbi.nlm.nih.gov\/17255259\/.","journal-title":"Clin Cancer Res"},{"key":"2579_CR70","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","volume":"24","author":"T Alvaro","year":"2006","unstructured":"Alvaro T, Lejeune M, Salvad\u00f3 M-T, Lopez C, Ja\u00e9n J, Bosch R, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24:5350\u20137 http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.06.4766.","journal-title":"J Clin Oncol"},{"key":"2579_CR71","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","volume":"27","author":"J Carreras","year":"2009","unstructured":"Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, Martinez A, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol. 2009;27:1470\u20136 http:\/\/ascopubs.org\/doi\/10.1200\/JCO.2008.18.0513.","journal-title":"J Clin Oncol"},{"key":"2579_CR72","doi-asserted-by":"publisher","first-page":"61425","DOI":"10.18632\/oncotarget.18251","volume":"8","author":"ZZ Yang","year":"2017","unstructured":"Yang ZZ, Kim HJ, Villasboas JC, Chen YP, Price-Troska TP, Jalali S, et al. Expression of LAG-3 defines exhaustion of intratumoral PD-1 + T cells and correlates with poor outcome in follicular lymphoma. Oncotarget. 2017;8:61425\u201339 https:\/\/pubmed.ncbi.nlm.nih.gov\/28977875\/.","journal-title":"Oncotarget"},{"key":"2579_CR73","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1172\/JCI31184","volume":"117","author":"JF Grosso","year":"2007","unstructured":"Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, de Marzo A, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Investig. 2007;117:3383\u201392 https:\/\/pubmed.ncbi.nlm.nih.gov\/17932562\/.","journal-title":"J Clin Investig"},{"key":"2579_CR74","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","volume":"40","author":"P Pathria","year":"2019","unstructured":"Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in Cancer. Trends Immunol. 2019;40:310\u201327 https:\/\/pubmed.ncbi.nlm.nih.gov\/30890304.","journal-title":"Trends Immunol"},{"key":"2579_CR75","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-019-0760-3","volume":"12","author":"Y Lin","year":"2019","unstructured":"Lin Y, Xu J, Lan H. Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J Hematol Oncol. 2019;12:76 https:\/\/pubmed.ncbi.nlm.nih.gov\/31300030\/.","journal-title":"J Hematol Oncol"},{"key":"2579_CR76","doi-asserted-by":"publisher","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","volume":"13","author":"M Taskinen","year":"2007","unstructured":"Taskinen M, Karjalainen-Lindsberg M-L, Nyman H, Eerola L-M, Lepp\u00e4 S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res. 2007;13:5784\u20139 http:\/\/clincancerres.aacrjournals.org\/cgi\/doi\/10.1158\/1078-0432.CCR-07-0778.","journal-title":"Clin Cancer Res"},{"key":"2579_CR77","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med. 2010;362:875\u201385 https:\/\/pubmed.ncbi.nlm.nih.gov\/20220182\/.","journal-title":"N Engl J Med"},{"key":"2579_CR78","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1182\/blood-2009-11-253260","volume":"115","author":"AJ Clear","year":"2010","unstructured":"Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, Hallam S, et al. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment. Blood. 2010;115:5053\u20136 https:\/\/pubmed.ncbi.nlm.nih.gov\/20375314\/.","journal-title":"Blood."},{"key":"2579_CR79","doi-asserted-by":"publisher","first-page":"30347","DOI":"10.1038\/srep30347","volume":"6","author":"L Shen","year":"2016","unstructured":"Shen L, Li H, Shi Y, Wang D, Gong J, Xun J, et al. M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma. Sci Rep. 2016;6:30347 https:\/\/pubmed.ncbi.nlm.nih.gov\/27464733\/.","journal-title":"Sci Rep"},{"key":"2579_CR80","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3389\/fimmu.2020.01731","volume":"11","author":"K Wu","year":"2020","unstructured":"Wu K, Lin K, Li X, Yuan X, Xu P, Ni P, et al. Redefining tumor-associated macrophage subpopulations and functions in the tumor microenvironment. Front Immunol. 2020;11:1731.","journal-title":"Front Immunol"},{"key":"2579_CR81","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/cells8121526","volume":"8","author":"AJ Petty","year":"2019","unstructured":"Petty AJ, Yang Y. Tumor-associated macrophages in hematologic malignancies: new insights and targeted therapies. Cells. 2019;8:1526 https:\/\/pubmed.ncbi.nlm.nih.gov\/32849616\/.","journal-title":"Cells."},{"issue":"2442","key":"2579_CR82","first-page":"2453","volume":"33","author":"A Papin","year":"2019","unstructured":"Papin A, Tessoulin B, Bellanger C, Moreau A, le Bris Y, Maisonneuve H, et al. CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages. Leukemia. 2019;33(2442):2453 https:\/\/pubmed.ncbi.nlm.nih.gov\/30940906\/.","journal-title":"Leukemia."},{"key":"2579_CR83","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1038\/s41375-021-01201-9","volume":"35","author":"JG Valero","year":"2021","unstructured":"Valero JG, Matas-C\u00e9spedes A, Arenas F, Rodriguez V, Carreras J, Serrat N, et al. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia. 2021;35:2635\u201349 https:\/\/pubmed.ncbi.nlm.nih.gov\/33731849\/.","journal-title":"Leukemia."},{"key":"2579_CR84","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369\u201382 https:\/\/pubmed.ncbi.nlm.nih.gov\/30718830\/.","journal-title":"Nat Rev Immunol"},{"key":"2579_CR85","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142:699\u2013713 https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867410008925.","journal-title":"Cell."},{"key":"2579_CR86","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","volume":"13","author":"E Eladl","year":"2020","unstructured":"Eladl E, Tremblay-Lemay R, Rastgoo N, Musani R, Chen W, Liu A, et al. Role of CD47 in hematological malignancies. J Hematol Oncol. 2020;13:96 https:\/\/pubmed.ncbi.nlm.nih.gov\/32677994\/.","journal-title":"J Hematol Oncol"},{"key":"2579_CR87","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1182\/blood-2011-02-338020","volume":"118","author":"MP Chao","year":"2011","unstructured":"Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011;118:4890\u2013901 https:\/\/ashpublications.org\/blood\/article\/118\/18\/4890\/29362\/Extranodal-dissemination-of-nonHodgkin-lymphoma.","journal-title":"Blood."},{"key":"2579_CR88","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-020-00437-8","volume":"6","author":"YH Huang","year":"2021","unstructured":"Huang YH, Cai K, Xu PP, Wang L, Huang CX, Fang Y, et al. CREBBP\/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2\/CSF1 axis. Signal Transduct Target Ther. 2021;6:10 https:\/\/pubmed.ncbi.nlm.nih.gov\/33431788\/.","journal-title":"Signal Transduct Target Ther"},{"key":"2579_CR89","doi-asserted-by":"crossref","unstructured":"Yan-Li L, Hu Q-Q, Wen Z-F, Li Q, Zhai Z-M. CCR2 expression promotes diffuse large B lymphoma cell survival and invasion. Lab Investig.\u00a0Lab Invest. 2022;102:1377\u201388.\u00a0https:\/\/pubmed.ncbi.nlm.nih.gov\/35851856\/.","DOI":"10.1038\/s41374-022-00824-5"},{"key":"2579_CR90","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jid.2019.11.018","volume":"140","author":"X Wu","year":"2020","unstructured":"Wu X, Singh R, Hsu DK, Zhou Y, Yu S, Han D, et al. A small molecule CCR2 antagonist depletes tumor macrophages and synergizes with anti\u2013PD-1 in a murine model of cutaneous T-cell lymphoma (CTCL). J Investig Dermatol. 2020;140:1390\u2013400 https:\/\/pubmed.ncbi.nlm.nih.gov\/31945344\/.","journal-title":"J Investig Dermatol"},{"key":"2579_CR91","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.3390\/cancers12123599","volume":"12","author":"N Ludwig","year":"2020","unstructured":"Ludwig N, Rubenich DS, Zar\u0119ba \u0141, Siewiera J, Pieper J, Braganhol E, et al. Potential roles of tumor cell-and stroma cell-derived small extracellular vesicles in promoting a pro-angiogenic tumor microenvironment. Cancers (Basel). 2020;12:3599 https:\/\/pubmed.ncbi.nlm.nih.gov\/33276428\/.","journal-title":"Cancers (Basel)"},{"key":"2579_CR92","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00262-018-2273-2","volume":"68","author":"WA Poles","year":"2019","unstructured":"Poles WA, Nishi EE, de Oliveira MB, Eug\u00eanio AIP, de Andrade TA, Campos AHFM, et al. Targeting the polarization of tumor-associated macrophages and modulating mir-155 expression might be a new approach to treat diffuse large B-cell lymphoma of the elderly. Cancer Immunol Immunother. 2019;68:269\u201382 https:\/\/pubmed.ncbi.nlm.nih.gov\/30430204\/.","journal-title":"Cancer Immunol Immunother"},{"key":"2579_CR93","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00262-020-02762-x","volume":"70","author":"M Moradi-Chaleshtori","year":"2021","unstructured":"Moradi-Chaleshtori M, Bandehpour M, Soudi S, Mohammadi-Yeganeh S, Hashemi SM. In vitro and in vivo evaluation of anti-tumoral effect of M1 phenotype induction in macrophages by miR-130 and miR-33 containing exosomes. Cancer Immunol Immunother. 2021;70:1323\u201339 https:\/\/pubmed.ncbi.nlm.nih.gov\/33140190\/.","journal-title":"Cancer Immunol Immunother"},{"key":"2579_CR94","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1158\/0008-5472.CAN-06-3037","volume":"67","author":"DI Gabrilovich","year":"2007","unstructured":"Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007;67:425 https:\/\/aacrjournals.org\/cancerres\/article\/67\/1\/425\/532949\/The-Terminology-Issue-for-Myeloid-Derived.","journal-title":"Cancer Res"},{"key":"2579_CR95","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-019-0772-z","volume":"12","author":"X Tian","year":"2019","unstructured":"Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J Hematol Oncol. 2019;12:84 https:\/\/pubmed.ncbi.nlm.nih.gov\/31438991\/.","journal-title":"J Hematol Oncol"},{"key":"2579_CR96","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37:208\u201320 https:\/\/pubmed.ncbi.nlm.nih.gov\/26858199\/.","journal-title":"Trends Immunol"},{"key":"2579_CR97","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/bjh.13198","volume":"168","author":"A Romano","year":"2015","unstructured":"Romano A, Parrinello NL, Vetro C, Forte S, Chiarenza A, Figuera A, et al. Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin lymphoma patients treated up-front with a risk-adapted strategy. Br J Haematol. 2015;168:689\u2013700 https:\/\/pubmed.ncbi.nlm.nih.gov\/25376846\/.","journal-title":"Br J Haematol"},{"key":"2579_CR98","doi-asserted-by":"publisher","first-page":"27676","DOI":"10.18632\/oncotarget.8507","volume":"7","author":"O Marini","year":"2016","unstructured":"Marini O, Spina C, Mimiola E, Cassaro A, Malerba G, Todeschini G, et al. Identification of granulocytic myeloid-derived suppressor cells (G-MDSCs) in the peripheral blood of Hodgkin and non-Hodgkin lymphoma patients. Oncotarget. 2016;7:27676\u201388 https:\/\/pubmed.ncbi.nlm.nih.gov\/27050283\/.","journal-title":"Oncotarget."},{"key":"2579_CR99","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","volume":"128","author":"I Azzaoui","year":"2016","unstructured":"Azzaoui I, Uhel F, Rossille D, Pangault C, Dulong J, le Priol J, et al. T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells. Blood. 2016;128:1081\u201392 https:\/\/pubmed.ncbi.nlm.nih.gov\/27338100\/.","journal-title":"Blood."},{"key":"2579_CR100","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/hon.2019","volume":"31","author":"T Tadmor","year":"2013","unstructured":"Tadmor T, Fell R, Polliack A, Attias D. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol. 2013;31:65\u201371 https:\/\/pubmed.ncbi.nlm.nih.gov\/22714941\/.","journal-title":"Hematol Oncol"},{"key":"2579_CR101","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.2147\/CMAR.S198886","volume":"11","author":"WH Ren","year":"2019","unstructured":"Ren WH, Zhang XR, Li WB, Feng Q, Feng HJ, Tong Y, et al. Exosomal miRNA-107 induces myeloid-derived suppressor cell expansion in gastric cancer. Cancer Manag Res. 2019;11:4023\u201340 https:\/\/pubmed.ncbi.nlm.nih.gov\/31190980\/.","journal-title":"Cancer Manag Res"},{"key":"2579_CR102","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1084\/jem.20061104","volume":"203","author":"P Serafini","year":"2006","unstructured":"Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203:2691\u2013702 https:\/\/pubmed.ncbi.nlm.nih.gov\/17101732\/.","journal-title":"J Exp Med"},{"key":"2579_CR103","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1111\/febs.14133","volume":"284","author":"Z Xu","year":"2017","unstructured":"Xu Z, Ji J, Xu J, Li D, Shi G, Liu F, et al. MiR-30a increases MDSC differentiation and immunosuppressive function by targeting SOCS3 in mice with B-cell lymphoma. FEBS J. 2017;284:2410\u201324 https:\/\/pubmed.ncbi.nlm.nih.gov\/28605567\/.","journal-title":"FEBS J"},{"key":"2579_CR104","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00262-018-2253-6","volume":"68","author":"H Grauers Wiktorin","year":"2019","unstructured":"Grauers Wiktorin H, Nilsson MS, Kiffin R, Sander FE, Lenox B, Rydstr\u00f6m A, et al. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1\/PD-L1 checkpoint blockade. Cancer Immunol Immunother. 2019;68:163\u201374 https:\/\/pubmed.ncbi.nlm.nih.gov\/30315349.","journal-title":"Cancer Immunol Immunother"},{"key":"2579_CR105","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-18-1133","volume":"25","author":"SL Locatelli","year":"2019","unstructured":"Locatelli SL, Careddu G, Serio S, Consonni FM, Maeda A, Viswanadha S, et al. Targeting cancer cells and tumor microenvironment in preclinical and clinical models of Hodgkin lymphoma using the dual PI3Kd\/G inhibitor RP6530. Clin Cancer Res. 2019;25:1098\u2013112 https:\/\/pubmed.ncbi.nlm.nih.gov\/30352904\/.","journal-title":"Clin Cancer Res"},{"key":"2579_CR106","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Investig. 2016;126:3130\u201344 https:\/\/pubmed.ncbi.nlm.nih.gov\/27454297\/.","journal-title":"J Clin Investig"},{"key":"2579_CR107","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","volume":"64","author":"RA Burga","year":"2015","unstructured":"Burga RA, Thorn M, Point GR, Guha P, Nguyen CT, Licata LA, et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother. 2015;64:817\u201329 https:\/\/pubmed.ncbi.nlm.nih.gov\/25850344\/.","journal-title":"Cancer Immunol Immunother"},{"key":"2579_CR108","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582\u201398 https:\/\/pubmed.ncbi.nlm.nih.gov\/27550820.","journal-title":"Nat Rev Cancer"},{"key":"2579_CR109","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","volume":"121","author":"A Orimo","year":"2005","unstructured":"Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion. Cell. 2005;121:335\u201348 https:\/\/pubmed.ncbi.nlm.nih.gov\/15882617\/.","journal-title":"Cell."},{"key":"2579_CR110","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99\u2013115 https:\/\/pubmed.ncbi.nlm.nih.gov\/30470818\/.","journal-title":"Nat Rev Drug Discov"},{"key":"2579_CR111","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2014.05.045","volume":"158","author":"R Scherz-Shouval","year":"2014","unstructured":"Scherz-Shouval R, Santagata S, Mendillo ML, Sholl LM, Ben-Aharon I, Beck AH, et al. The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy. Cell. 2014;158:564\u201378 https:\/\/pubmed.ncbi.nlm.nih.gov\/25083868\/.","journal-title":"Cell."},{"key":"2579_CR112","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/ncb2756","volume":"15","author":"F Calvo","year":"2013","unstructured":"Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013;15:637\u201346 https:\/\/pubmed.ncbi.nlm.nih.gov\/23708000\/.","journal-title":"Nat Cell Biol"},{"key":"2579_CR113","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/cmi.2017.35","volume":"14","author":"A Sarvaria","year":"2017","unstructured":"Sarvaria A, Madrigal JA, Saudemont A. B cell regulation in cancer and anti-tumor immunity. Cell Mol Immunol. 2017;14:662\u201374 https:\/\/pubmed.ncbi.nlm.nih.gov\/28626234\/.","journal-title":"Cell Mol Immunol"},{"key":"2579_CR114","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1152\/ajpcell.1999.277.1.C1","volume":"277","author":"DW Powell","year":"1999","unstructured":"Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol Cell Physiol. 1999;277:C1\u20139.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2579_CR115","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2016-08-737239","volume":"129","author":"S Pandey","year":"2017","unstructured":"Pandey S, Mourcin F, Marchand T, Nayar S, Guirriec M, Pangault C, et al. IL-4\/CXCL12 loop is a key regulator of lymphoid stroma function in follicular lymphoma. Blood. 2017;129:2507\u201318 https:\/\/pubmed.ncbi.nlm.nih.gov\/28202459\/.","journal-title":"Blood."},{"key":"2579_CR116","doi-asserted-by":"publisher","first-page":"16471","DOI":"10.18632\/oncotarget.4106","volume":"6","author":"M Gr\u00e9goire","year":"2015","unstructured":"Gr\u00e9goire M, Guilloton F, Pangault C, Mourcin F, Sok P, Latour M, et al. Neutrophils trigger a NF-\u039aB dependent polarization of tumorsupportive stromal cells in germinal center B-cell lymphomas. Oncotarget. 2015;6:16471\u201387 https:\/\/pubmed.ncbi.nlm.nih.gov\/26158216\/.","journal-title":"Oncotarget."},{"key":"2579_CR117","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1182\/blood-2011-08-370908","volume":"119","author":"F Guilloton","year":"2012","unstructured":"Guilloton F, Caron G, M\u00e9nard C, Pangault C, Am\u00e9-Thomas P, Dulong J, et al. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood. 2012;119:2556\u201367 http:\/\/ashpublications.org\/blood\/article-pdf\/119\/11\/2556\/1350217\/zh801112002556.pdf.","journal-title":"Blood."},{"key":"2579_CR118","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fcell.2018.00098","volume":"6","author":"M Haro","year":"2018","unstructured":"Haro M, Orsulic S. A paradoxical correlation of cancer-associated fibroblasts with survival outcomes in B-cell lymphomas and carcinomas. Front Cell Dev Biol. 2018;6:98 https:\/\/pubmed.ncbi.nlm.nih.gov\/30211161\/.","journal-title":"Front Cell Dev Biol"},{"key":"2579_CR119","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1182\/blood-2017-10-810630","volume":"131","author":"A Stelling","year":"2018","unstructured":"Stelling A, Hashwah H, Bertram K, Manz MG, Tzankov A, M\u00fcller A. The tumor suppressive TGF-b\/SMAD1\/S1PR2 signaling axis is recurrently inactivated in diffuse large B-cell lymphoma. Blood. 2018;131:2235\u201346 https:\/\/pubmed.ncbi.nlm.nih.gov\/29615404\/.","journal-title":"Blood."},{"key":"2579_CR120","doi-asserted-by":"publisher","first-page":"a0222236","DOI":"10.1101\/cshperspect.a022236","volume":"9","author":"S Sanjabi","year":"2017","unstructured":"Sanjabi S, Oh SA, Li MO. Regulation of the immune response by TGF-\u03b2: from conception to autoimmunity and infection. Cold Spring Harb Perspect Biol. 2017;9:a0222236 https:\/\/pubmed.ncbi.nlm.nih.gov\/28108486.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2579_CR121","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ni1582","volume":"9","author":"E Vivier","year":"2008","unstructured":"Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9:503\u201310 https:\/\/pubmed.ncbi.nlm.nih.gov\/18425107\/.","journal-title":"Nat Immunol"},{"key":"2579_CR122","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.1073\/pnas.83.15.5688","volume":"83","author":"A Harel-Bellan","year":"1986","unstructured":"Harel-Bellan A, Quillet A, Marchiol C, DeMars R, Tursz T, Fradelizi D. Natural killer susceptibility of human cells may be regulated by genes in the HLA region on chromosome 6. Proc Natl Acad Sci U S A. 1986;83:5688\u201392 https:\/\/pubmed.ncbi.nlm.nih.gov\/2426704\/.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2579_CR123","doi-asserted-by":"publisher","first-page":"e1226720","DOI":"10.1080\/2162402X.2016.1226720","volume":"5","author":"EM McWilliams","year":"2016","unstructured":"McWilliams EM, Mele JM, Cheney C, Timmerman EA, Fiazuddin F, Strattan EJ, et al. Therapeutic CD94\/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology. 2016;5:e1226720 https:\/\/pubmed.ncbi.nlm.nih.gov\/27853650\/.","journal-title":"Oncoimmunology."},{"key":"2579_CR124","doi-asserted-by":"crossref","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immun. 2022:1\u201316 https:\/\/www.nature.com\/articles\/s41577-022-00732-1.","DOI":"10.1038\/s41577-022-00732-1"},{"key":"2579_CR125","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","volume":"319","author":"K K\u00e4rre","year":"1986","unstructured":"K\u00e4rre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature. 1986;319:675\u20138 https:\/\/pubmed.ncbi.nlm.nih.gov\/3951539\/.","journal-title":"Nature."},{"key":"2579_CR126","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.4049\/jimmunol.138.12.4539","volume":"138","author":"WE Seaman","year":"1987","unstructured":"Seaman WE, Sleisenger M, Eriksson E, Koo GC. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J Immunol. 1987;138:4539\u201344.","journal-title":"J Immunol"},{"key":"2579_CR127","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1084\/jem.20031981","volume":"199","author":"SEA Street","year":"2004","unstructured":"Street SEA, Hayakawa Y, Zhan Y, Lew AM, MacGregor D, Jamieson AM, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and \u03b3\u03b4 T cells. J Exp Med. 2004;199:879\u201384 https:\/\/pubmed.ncbi.nlm.nih.gov\/15007091\/.","journal-title":"J Exp Med"},{"key":"2579_CR128","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/intimm\/13.4.459","volume":"13","author":"MJ Smyth","year":"2001","unstructured":"Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001;13:459\u201363 https:\/\/pubmed.ncbi.nlm.nih.gov\/11282985\/.","journal-title":"Int Immunol"},{"key":"2579_CR129","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.immuni.2020.10.020","volume":"53","author":"E Bonavita","year":"2020","unstructured":"Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, et al. Antagonistic inflammatory phenotypes dictate tumor fate and response to immune checkpoint blockade. Immunity. 2020;53:1215\u201329 https:\/\/pubmed.ncbi.nlm.nih.gov\/33220234\/.","journal-title":"Immunity."},{"key":"2579_CR130","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2018.09.016","volume":"49","author":"A Marcus","year":"2018","unstructured":"Marcus A, Mao AJ, Lensink-Vasan M, Wang LA, Vance RE, Raulet DH. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response. Immunity. 2018;49:754\u201363 https:\/\/pubmed.ncbi.nlm.nih.gov\/30332631\/.","journal-title":"Immunity."},{"key":"2579_CR131","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1158\/0008-5472.CAN-16-2490","volume":"77","author":"FS Varn","year":"2017","unstructured":"Varn FS, Wang Y, Mullins DW, Fiering S, Cheng C. Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment. Cancer Res. 2017;77:1271\u201382 https:\/\/pubmed.ncbi.nlm.nih.gov\/28126714\/.","journal-title":"Cancer Res"},{"key":"2579_CR132","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1158\/2159-8290.CD-20-0655","volume":"11","author":"B C\u00f3zar","year":"2021","unstructured":"C\u00f3zar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-infiltrating natural killer cells. Cancer Discov. 2021;11:34\u201344 https:\/\/pubmed.ncbi.nlm.nih.gov\/33277307\/.","journal-title":"Cancer Discov"},{"key":"2579_CR133","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1158\/2326-6066.CIR-18-0500","volume":"7","author":"J Cursons","year":"2019","unstructured":"Cursons J, Souza-Fonseca-Guimaraes F, Foroutan M, Anderson A, Hollande F, Hediyeh-Zadeh S, et al. A gene signature predicting natural killer cell infiltration and improved survival in melanoma patients. Cancer Immunol Res. 2019;7:1162\u201374.","journal-title":"Cancer Immunol Res"},{"key":"2579_CR134","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1073\/pnas.0730640100","volume":"100","author":"R Castriconi","year":"2003","unstructured":"Castriconi R, Cantoni C, della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor \u03b21 inhibits expression of NKP30 and NKG2d receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A. 2003;100:4120\u20135 https:\/\/pubmed.ncbi.nlm.nih.gov\/12646700\/.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2579_CR135","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/ni.3800","volume":"18","author":"Y Gao","year":"2017","unstructured":"Gao Y, Souza-Fonseca-Guimaraes F, Bald T, Ng SS, Young A, Ngiow SF, et al. Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells. Nat Immunol. 2017;18:1004\u201315 https:\/\/pubmed.ncbi.nlm.nih.gov\/28759001\/.","journal-title":"Nat Immunol"},{"key":"2579_CR136","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.cell.2015.08.015","volume":"162","author":"S Zelenay","year":"2015","unstructured":"Zelenay S, van der Veen AG, B\u00f6ttcher JP, Snelgrove KJ, Rogers N, Acton SE, et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell. 2015;162:1257\u201370.","journal-title":"Cell."},{"key":"2579_CR137","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","volume":"78","author":"A Young","year":"2018","unstructured":"Young A, Ngiow SF, Gao Y, Patch AM, Barkauskas DS, Messaoudene M, et al. A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment. Cancer Res. 2018;78:1003\u201316 https:\/\/pubmed.ncbi.nlm.nih.gov\/29229601\/.","journal-title":"Cancer Res"},{"key":"2579_CR138","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1600-065X.2006.00445.x","volume":"214","author":"F Ghiringhelli","year":"2006","unstructured":"Ghiringhelli F, M\u00e9nard C, Martin F, Zitvogel L. The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression. Immunol Rev. 2006;214:229\u201338 https:\/\/pubmed.ncbi.nlm.nih.gov\/17100888\/.","journal-title":"Immunol Rev"},{"key":"2579_CR139","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1084\/jem.20130960","volume":"210","author":"Y Kerdiles","year":"2013","unstructured":"Kerdiles Y, Ugolini S, Vivier E. T cell regulation of natural killer cells. J Exp Med. 2013;210:1065\u20138 https:\/\/pubmed.ncbi.nlm.nih.gov\/23733834\/.","journal-title":"J Exp Med"},{"key":"2579_CR140","doi-asserted-by":"publisher","first-page":"17858","DOI":"10.1073\/pnas.0903474106","volume":"106","author":"N Stanietsky","year":"2009","unstructured":"Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009;106:17858\u201363 https:\/\/pubmed.ncbi.nlm.nih.gov\/19815499\/.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2579_CR141","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ni.2850","volume":"15","author":"CJ Chan","year":"2014","unstructured":"Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, et al. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol. 2014;15:531\u20138 https:\/\/pubmed.ncbi.nlm.nih.gov\/24658051\/.","journal-title":"Nat Immunol"},{"key":"2579_CR142","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu J, Hodgins JJ, Marathe M, Nicolai CJ, Bourgeois-Daigneault MC, Trevino TN, et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J Clin Investig. 2018;128:4654\u201368 https:\/\/pubmed.ncbi.nlm.nih.gov\/30198904\/.","journal-title":"J Clin Investig"},{"key":"2579_CR143","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2326-6066.CIR-18-0062","volume":"6","author":"F Concha-Benavente","year":"2018","unstructured":"Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 mediates dysfunction in activated PD-1 \u00fe NK cells in head and neck cancer patients. Cancer Immunol Res. 2018;6:1548\u201360 https:\/\/pubmed.ncbi.nlm.nih.gov\/30282672\/.","journal-title":"Cancer Immunol Res"},{"key":"2579_CR144","doi-asserted-by":"publisher","first-page":"e20200839","DOI":"10.1084\/jem.20200839","volume":"218","author":"T Deuse","year":"2021","unstructured":"Deuse T, Hu X, Agbor-Enoh S, Jang MK, Alawi M, Saygi C, et al. The SIRP\u03b1-CD47 immune checkpoint in NK cells. J Exp Med. 2021;218:e20200839 https:\/\/pubmed.ncbi.nlm.nih.gov\/33416832\/.","journal-title":"J Exp Med"},{"key":"2579_CR145","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","volume":"116","author":"DM Benson","year":"2010","unstructured":"Benson DM, Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, et al. The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116:2286\u201394 https:\/\/pubmed.ncbi.nlm.nih.gov\/20460501\/.","journal-title":"Blood."},{"key":"2579_CR146","doi-asserted-by":"publisher","first-page":"72961","DOI":"10.18632\/oncotarget.12150","volume":"7","author":"A Beldi-Ferchiou","year":"2016","unstructured":"Beldi-Ferchiou A, Lambert M, Dogniaux S, V\u00e9ly F, Vivier E, Olive D, et al. PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. Oncotarget. 2016;7:72961\u201377 https:\/\/pubmed.ncbi.nlm.nih.gov\/27662664\/.","journal-title":"Oncotarget."},{"key":"2579_CR147","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/onc.2017.209","volume":"36","author":"Y Liu","year":"2017","unstructured":"Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36:6143\u201353 https:\/\/pubmed.ncbi.nlm.nih.gov\/28692048\/.","journal-title":"Oncogene."},{"key":"2579_CR148","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","volume":"131","author":"F Vari","year":"2018","unstructured":"Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, et al. Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018;131:1809\u201319 https:\/\/pubmed.ncbi.nlm.nih.gov\/29449276\/.","journal-title":"Blood."},{"key":"2579_CR149","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","volume":"19","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Bi J, Zheng X, Chen Y, Wang H, Wu W, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity. Nat Immunol. 2018;19:723\u201332 https:\/\/pubmed.ncbi.nlm.nih.gov\/29915296\/.","journal-title":"Nat Immunol"},{"key":"2579_CR150","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andr\u00e9","year":"2018","unstructured":"Andr\u00e9 P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731\u201343 https:\/\/pubmed.ncbi.nlm.nih.gov\/30503213\/.","journal-title":"Cell."},{"key":"2579_CR151","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1084\/jem.20082874","volume":"206","author":"SM McWhirter","year":"2009","unstructured":"McWhirter SM, Barbalat R, Monroe KM, Fontana MF, Hyodo M, Joncker NT, et al. A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med. 2009;206:1899\u2013911 https:\/\/pubmed.ncbi.nlm.nih.gov\/19652017\/.","journal-title":"J Exp Med"},{"key":"2579_CR152","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2019.04.041","volume":"177","author":"L Gauthier","year":"2019","unstructured":"Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, et al. Multifunctional natural killer cell engagers targeting NKp46 trigger protective tumor immunity. Cell. 2019;177:1701\u201313 https:\/\/pubmed.ncbi.nlm.nih.gov\/31155232\/.","journal-title":"Cell."},{"key":"2579_CR153","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1182\/bloodadvances.2017012369","volume":"2","author":"D Sarhan","year":"2018","unstructured":"Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, et al. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. Blood Adv. 2018;2:1459\u201360 https:\/\/pubmed.ncbi.nlm.nih.gov\/29941459\/.","journal-title":"Blood Adv"},{"key":"2579_CR154","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-12-3558","volume":"73","author":"YH Chang","year":"2013","unstructured":"Chang YH, Connolly J, Shimasaki N, Mimura K, Kono K, Campana D. A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res. 2013;73:1777\u201386 https:\/\/pubmed.ncbi.nlm.nih.gov\/23302231\/.","journal-title":"Cancer Res"},{"key":"2579_CR155","first-page":"363","volume":"7","author":"R Parihar","year":"2019","unstructured":"Parihar R, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, et al. NK cells expressing a chimeric activating receptor eliminate MDSCs and rescue impaired CAR-T cell activity against solid tumors. Cancer. Immunol Res. 2019;7:363\u201375 https:\/\/pubmed.ncbi.nlm.nih.gov\/30651290\/.","journal-title":"Immunol Res"},{"key":"2579_CR156","doi-asserted-by":"publisher","first-page":"e28147","DOI":"10.4161\/onci.28147","volume":"3","author":"H Klingemann","year":"2014","unstructured":"Klingemann H. Are natural killer cells superior CAR drivers? Oncoimmunology. 2014;3:e28147 https:\/\/pubmed.ncbi.nlm.nih.gov\/25340009\/.","journal-title":"Oncoimmunology."},{"key":"2579_CR157","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederst\u00e4dt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22:557\u201375 https:\/\/www.nature.com\/articles\/s41568-022-00491-0.","journal-title":"Nat Rev Cancer"},{"key":"2579_CR158","doi-asserted-by":"publisher","first-page":"aaa6566","DOI":"10.1126\/science.aaa6566","volume":"348","author":"G Eberl","year":"2015","unstructured":"Eberl G, Colonna M, Santo JPD, McKenzie ANJ. Innate lymphoid cells: a new paradigm in immunology. Science. 2015;348:aaa6566 https:\/\/pubmed.ncbi.nlm.nih.gov\/25999512\/.","journal-title":"Science."},{"key":"2579_CR159","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/978-1-4939-8549-4_21","volume":"1803","author":"ED Tait Wojno","year":"2018","unstructured":"Tait Wojno ED, Beamer CA. Isolation and identification of innate lymphoid cells (ILCs) for immunotoxicity testing. Methods Mol Biol. 2018;1803:353\u201370 https:\/\/pubmed.ncbi.nlm.nih.gov\/29882149\/.","journal-title":"Methods Mol Biol"},{"key":"2579_CR160","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.immuni.2014.09.005","volume":"41","author":"A Diefenbach","year":"2014","unstructured":"Diefenbach A, Colonna M, Koyasu S. Development, differentiation, and diversity of innate lymphoid cells. Immunity. 2014;41:354\u201365 https:\/\/pubmed.ncbi.nlm.nih.gov\/25238093\/.","journal-title":"Immunity."},{"key":"2579_CR161","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.immuni.2014.09.006","volume":"41","author":"ANJ McKenzie","year":"2014","unstructured":"McKenzie ANJ, Spits H, Eberl G. Innate lymphoid cells in inflammation and immunity. Immunity. 2014;41:366\u201374 https:\/\/pubmed.ncbi.nlm.nih.gov\/25238094\/.","journal-title":"Immunity."},{"issue":"14","key":"2579_CR162","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/ni.2534","volume":"14","author":"JH Bernink","year":"2013","unstructured":"Bernink JH, Peters CP, Munneke M, te Velde AA, Meijer SL, Weijer K, et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol. 2013;14(14):221\u20139 https:\/\/pubmed.ncbi.nlm.nih.gov\/23334791\/.","journal-title":"Nat Immunol"},{"key":"2579_CR163","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.it.2016.11.004","volume":"38","author":"LK Mackay","year":"2017","unstructured":"Mackay LK, Kallies A. Transcriptional regulation of tissue-resident lymphocytes. Trends Immunol. 2017;38:94\u2013103 https:\/\/pubmed.ncbi.nlm.nih.gov\/27939451\/.","journal-title":"Trends Immunol"},{"key":"2579_CR164","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1084\/jem.20160525","volume":"213","author":"ED Tait Wojno","year":"2016","unstructured":"Tait Wojno ED, Artis D. Emerging concepts and future challenges in innate lymphoid cell biology. J Exp Med. 2016;213:2229\u201348 https:\/\/pubmed.ncbi.nlm.nih.gov\/27811053\/.","journal-title":"J Exp Med"},{"key":"2579_CR165","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1038\/ni.2617","volume":"14","author":"P Licona-Lim\u00f3n","year":"2013","unstructured":"Licona-Lim\u00f3n P, Kim LK, Palm NW, Flavell RA. TH2, allergy and group 2 innate lymphoid cells. Nat Immunol. 2013;14:536\u201342 https:\/\/pubmed.ncbi.nlm.nih.gov\/23685824\/.","journal-title":"Nat Immunol"},{"key":"2579_CR166","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/978-1-4614-6217-0_2","volume":"785","author":"YY Hwang","year":"2013","unstructured":"Hwang YY, McKenzie ANJ. Innate lymphoid cells in immunity and disease. Adv Exp Med Biol. 2013;785:9\u201326 https:\/\/pubmed.ncbi.nlm.nih.gov\/23456833\/.","journal-title":"Adv Exp Med Biol"},{"key":"2579_CR167","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.coi.2015.11.008","volume":"38","author":"ND Huntington","year":"2016","unstructured":"Huntington ND, Carpentier S, Vivier E, Belz GT. Innate lymphoid cells: parallel checkpoints and coordinate interactions with T cells. Curr Opin Immunol. 2016;38:86\u201393 https:\/\/pubmed.ncbi.nlm.nih.gov\/26736074\/.","journal-title":"Curr Opin Immunol"},{"key":"2579_CR168","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/eji.201242639","volume":"42","author":"J Mj\u00f6sberg","year":"2012","unstructured":"Mj\u00f6sberg J, Bernink J, Peters C, Spits H. Transcriptional control of innate lymphoid cells. Eur J Immunol. 2012;42:1916\u201323 https:\/\/pubmed.ncbi.nlm.nih.gov\/22865043\/.","journal-title":"Eur J Immunol"},{"key":"2579_CR169","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ni.3489","volume":"17","author":"CSN Klose","year":"2016","unstructured":"Klose CSN, Artis D. Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol. 2016;17:765\u201374 https:\/\/pubmed.ncbi.nlm.nih.gov\/27328006\/.","journal-title":"Nat Immunol"},{"key":"2579_CR170","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.cell.2014.03.030","volume":"157","author":"CSN Klose","year":"2014","unstructured":"Klose CSN, Flach M, M\u00f6hle L, Rogell L, Hoyler T, Ebert K, et al. Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages. Cell. 2014;157:340\u201356 https:\/\/pubmed.ncbi.nlm.nih.gov\/24725403\/.","journal-title":"Cell."},{"key":"2579_CR171","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nature13047","volume":"508","author":"MG Constantinides","year":"2014","unstructured":"Constantinides MG, McDonald BD, Verhoef PA, Bendelac A. A committed precursor to innate lymphoid cells. Nature. 2014;508:397\u2013401 https:\/\/pubmed.ncbi.nlm.nih.gov\/24509713\/.","journal-title":"Nature."},{"key":"2579_CR172","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/ni.3444","volume":"17","author":"SM Bal","year":"2016","unstructured":"Bal SM, Bernink JH, Nagasawa M, Groot J, Shikhagaie MM, Golebski K, et al. IL-1\u03b2, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol. 2016;17:636\u201345 https:\/\/pubmed.ncbi.nlm.nih.gov\/27111145\/.","journal-title":"Nat Immunol"},{"key":"2579_CR173","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/ni.3447","volume":"17","author":"Y Ohne","year":"2016","unstructured":"Ohne Y, Silver JS, Thompson-Snipes LA, Collet MA, Blanck JP, Cantarel BL, et al. IL-1 is a critical regulator of group 2 innate lymphoid cell function and plasticity. Nat Immunol. 2016;17:646\u201355 https:\/\/pubmed.ncbi.nlm.nih.gov\/27111142\/.","journal-title":"Nat Immunol"},{"key":"2579_CR174","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41467-017-00678-2","volume":"8","author":"S Trabanelli","year":"2017","unstructured":"Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salom\u00e9 B, Lecciso M, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017;8:593 https:\/\/pubmed.ncbi.nlm.nih.gov\/28928446\/.","journal-title":"Nat Commun"},{"key":"2579_CR175","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4049\/jimmunol.1101270","volume":"188","author":"M Ikutani","year":"2012","unstructured":"Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, et al. Identification of innate IL-5\u2013producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol. 2012;188:703\u201313 https:\/\/pubmed.ncbi.nlm.nih.gov\/22174445\/.","journal-title":"J Immunol"},{"key":"2579_CR176","doi-asserted-by":"publisher","first-page":"30555","DOI":"10.1038\/srep30555","volume":"6","author":"I Saranchova","year":"2016","unstructured":"Saranchova I, Han J, Huang H, Fenninger F, Choi KB, Munro L, et al. Discovery of a metastatic immune escape mechanism initiated by the loss of expression of the tumour biomarker Interleukin-33. Sci Rep. 2016;6:30555 https:\/\/pubmed.ncbi.nlm.nih.gov\/27619158\/.","journal-title":"Sci Rep"},{"key":"2579_CR177","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.immuni.2015.01.020","volume":"42","author":"DMW Zaiss","year":"2015","unstructured":"Zaiss DMW, Gause WC, Osborne LC, Artis D. Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair. Immunity. 2015;42:216\u201326 https:\/\/pubmed.ncbi.nlm.nih.gov\/25692699\/.","journal-title":"Immunity."},{"key":"2579_CR178","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1189\/jlb.0213084","volume":"94","author":"JK Bando","year":"2013","unstructured":"Bando JK, Nussbaum JC, Liang H-E, Locksley RM. Type 2 innate lymphoid cells constitutively express arginase-I in the na\u00efve and inflamed lung. J Leukoc Biol. 2013;94:877\u201384 https:\/\/pubmed.ncbi.nlm.nih.gov\/23924659\/.","journal-title":"J Leukoc Biol"},{"key":"2579_CR179","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.immuni.2013.02.010","volume":"38","author":"A Fuchs","year":"2013","unstructured":"Fuchs A, Vermi W, Lee JS, Lonardi S, Gilfillan S, Newberry RD, et al. Intraepithelial type 1 innate lymphoid cells are a unique subset of il-12- and il-15-responsive ifn-\u03b3-producing cells. Immunity. 2013;38:769\u201381 https:\/\/pubmed.ncbi.nlm.nih.gov\/23453631\/.","journal-title":"Immunity."},{"key":"2579_CR180","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.immuni.2015.06.019","volume":"43","author":"JH Bernink","year":"2015","unstructured":"Bernink JH, Krabbendam L, Germar K, de Jong E, Gronke K, Kofoed-Nielsen M, et al. Interleukin-12 and -23 control plasticity of Cd127+ group 1 and group 3 innate lymphoid cells in the intestinal Lamina Propria. Immunity. 2015;43:146\u201360.","journal-title":"Immunity."},{"key":"2579_CR181","doi-asserted-by":"publisher","first-page":"e10066","DOI":"10.7554\/eLife.10066","volume":"5","author":"C Pearson","year":"2016","unstructured":"Pearson C, Thornton EE, McKenzie B, Schaupp AL, Huskens N, Griseri T, et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. Elife. 2016;5:e10066 https:\/\/pubmed.ncbi.nlm.nih.gov\/26780670\/.","journal-title":"Elife."},{"key":"2579_CR182","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.immuni.2015.07.008","volume":"43","author":"T Griseri","year":"2015","unstructured":"Griseri T, Arnold IC, Pearson C, Krausgruber T, Schiering C, Franchini F, et al. Granulocyte macrophage Colony-stimulating factor-activated eosinophils promote Interleukin-23 driven chronic colitis. Immunity. 2015;43:187\u201399 https:\/\/pubmed.ncbi.nlm.nih.gov\/26200014\/.","journal-title":"Immunity."},{"key":"2579_CR183","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.bbrc.2011.03.021","volume":"407","author":"J Liu","year":"2011","unstructured":"Liu J, Duan Y, Cheng X, Chen X, Xie W, Long H, et al. IL-17 is associated with poor prognosis and promotes angiogenesis via stimulating VEGF production of cancer cells in colorectal carcinoma. Biochem Biophys Res Commun. 2011;407:348\u201354 https:\/\/pubmed.ncbi.nlm.nih.gov\/21396350\/.","journal-title":"Biochem Biophys Res Commun"},{"key":"2579_CR184","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-10-2907","volume":"71","author":"M Tosolini","year":"2011","unstructured":"Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res. 2011;71:1263\u201371 https:\/\/pubmed.ncbi.nlm.nih.gov\/21303976\/.","journal-title":"Cancer Res"},{"key":"2579_CR185","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00428-019-02698-3","volume":"476","author":"RL King","year":"2020","unstructured":"King RL, Goodlad JR, Calaminici M, Dotlic S, Montes-Moreno S, Oschlies I, et al. Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis. Virchows Arch. 2020;476:647\u201365 https:\/\/pubmed.ncbi.nlm.nih.gov\/31863183\/.","journal-title":"Virchows Arch"},{"key":"2579_CR186","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/bjh.14392","volume":"176","author":"R Kridel","year":"2017","unstructured":"Kridel R, Telio D, Villa D, Sehn LH, Gerrie AS, Shenkier T, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017;176:210\u201321 https:\/\/pubmed.ncbi.nlm.nih.gov\/27739058\/.","journal-title":"Br J Haematol"},{"key":"2579_CR187","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","volume":"20","author":"JEC Bromberg","year":"2019","unstructured":"Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2019;20:216\u201328 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30630772.","journal-title":"Lancet Oncol"},{"key":"2579_CR188","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-022-30050-y","volume":"13","author":"J Radke","year":"2022","unstructured":"Radke J, Ishaque N, Koll R, Gu Z, Schumann E, Sieverling L, et al. The genomic and transcriptional landscape of primary central nervous system lymphoma. Nat Commun. 2022;13:1\u201320 https:\/\/www.nature.com\/articles\/s41467-022-30050-y.","journal-title":"Nat Commun"},{"key":"2579_CR189","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy B, Roemer MGM, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127:869\u201381 http:\/\/www.bloodjournal.org\/cgi\/doi\/10.1182\/blood-2015-10-673236.","journal-title":"Blood"},{"key":"2579_CR190","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature09671","volume":"470","author":"VN Ngo","year":"2011","unstructured":"Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim K-H, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470:115\u20139 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21179087.","journal-title":"Nature"},{"key":"2579_CR191","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","volume":"20","author":"M Challa-Malladi","year":"2011","unstructured":"Challa-Malladi M, Lieu YK, Califano O, Holmes A, Bhagat G, Murty V v., et al. Combined genetic inactivation of Beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B-cell lymphoma. Cancer Cell 2011;20:728. \/pmc\/articles\/PMC3660995\/.","journal-title":"Cancer Cell"},{"key":"2579_CR192","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","volume":"471","author":"C Steidl","year":"2011","unstructured":"Steidl C, Shah SP, Woolcock BW, Rui L, Kawahara M, Farinha P, et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature. 2011;471:377\u201381 https:\/\/pubmed.ncbi.nlm.nih.gov\/21368758\/.","journal-title":"Nature."},{"key":"2579_CR193","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s00262-020-02575-y","volume":"69","author":"L Marcelis","year":"2020","unstructured":"Marcelis L, Antoranz A, Delsupehe AM, Biesemans P, Ferreiro JF, Debackere K, et al. In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother. 2020;69:1751\u201366 https:\/\/pubmed.ncbi.nlm.nih.gov\/32335702\/.","journal-title":"Cancer Immunol Immunother"},{"key":"2579_CR194","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41417-020-00259-4","volume":"28","author":"J Guo","year":"2021","unstructured":"Guo J, Tang Q. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. Cancer Gene Ther. 2021;28:1075\u201387 https:\/\/pubmed.ncbi.nlm.nih.gov\/33500535\/.","journal-title":"Cancer Gene Ther"},{"key":"2579_CR195","doi-asserted-by":"publisher","first-page":"e90196","DOI":"10.1172\/jci.insight.90196","volume":"2","author":"P Mondello","year":"2017","unstructured":"Mondello P, Brea EJ, de Stanchina E, Toska E, Chang AY, Fennell M, et al. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. JCI Insight. 2017;2:e90196 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28352655.","journal-title":"JCI Insight"},{"key":"2579_CR196","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017;7:1018\u201329 http:\/\/cancerdiscovery.aacrjournals.org\/lookup\/doi\/10.1158\/2159-8290.CD-17-0613.","journal-title":"Cancer Discov"},{"key":"2579_CR197","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by Ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31:833\u2013843.e5 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28552327.","journal-title":"Cancer Cell"},{"key":"2579_CR198","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.critrevonc.2019.06.009","volume":"141","author":"P Mondello","year":"2019","unstructured":"Mondello P, Mian M, Bertoni F. Primary central nervous system lymphoma: novel precision therapies. Crit Rev Oncol Hematol. 2019;141:139\u201345 http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31295667.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2579_CR199","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.cell.2020.09.001","volume":"183","author":"BY Nabet","year":"2020","unstructured":"Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell. 2020;183:363\u201376 https:\/\/pubmed.ncbi.nlm.nih.gov\/33007267\/.","journal-title":"Cell."},{"key":"2579_CR200","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/0008-5472.CAN-15-1707","volume":"76","author":"R Tavar\u00e9","year":"2016","unstructured":"Tavar\u00e9 R, Escuin-Ordinas H, Mok S, McCracken MN, Zettlitz KA, Salazar FB, et al. An effective immuno-PET imaging method to monitor CD8-dependent responses to immunotherapy. Cancer Res. 2016;76:73\u201382 https:\/\/pubmed.ncbi.nlm.nih.gov\/26573799\/.","journal-title":"Cancer Res"},{"key":"2579_CR201","first-page":"720","volume":"63","author":"MD Farwell","year":"2022","unstructured":"Farwell MD, Gamache RF, Babazada H, Hellmann MD, Harding JJ, Korn R, et al. CD8-targeted PET imaging of tumor-infiltrating T cells in patients with Cancer: a phase i first-in-humans study of 89Zr-Df-IAB22M2C, a radiolabeled anti-CD8 Minibody. J Nucl Med. 2022;63:720\u20136 https:\/\/pubmed.ncbi.nlm.nih.gov\/34413145\/.","journal-title":"J Nucl Med"},{"key":"2579_CR202","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13550-022-00877-z","volume":"12","author":"D Gosmann","year":"2022","unstructured":"Gosmann D, Russelli L, Weber WA, Schwaiger M, Krackhardt AM, D\u2019Alessandria C. Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy. EJNMMI Res. 2022;12:5 https:\/\/pubmed.ncbi.nlm.nih.gov\/35099641\/.","journal-title":"EJNMMI Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02579-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02579-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02579-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T06:23:06Z","timestamp":1679206986000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02579-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":202,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2579"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02579-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]},"assertion":[{"value":"28 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. No writing assistance was utilized in the production of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"362"}}